Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 16-Week Open-Label Study of the Effects of Treatment With Pimavanserin on Activities of Daily Living in Subjects With Parkinson's Disease Psychosis

NCT04292223 is registered in ClinicalTrials.gov with ACADIA Pharmaceuticals Inc. as lead sponsor.

NCT NCT04292223
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04292223 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 16-Week Open-Label Study of the Effects of Treatment With Pimavanserin on Activities of Daily Living in Subjects With Parkinson's Disease Psychosis
Lead sponsor
ACADIA Pharmaceuticals Inc.
Phase
Phase 4
Overall status
Completed
Start date
February 10, 2020
Completion date
April 26, 2022
Enrollment
29 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

parkinson disease psychosis